Benzimidazole derivatives as potent and isoform selective tumor-associated carbonic anhydrase IX/XII inhibitors
作者:Azize Gizem Uslu、Tuğçe Gür Maz、Alessio Nocentini、Erden Banoglu、Claudiu T. Supuran、Burcu Çalışkan
DOI:10.1016/j.bioorg.2019.103544
日期:2020.1
We describe the synthesis of a series of 2-arylbenzimidazole derivatives bearing sulfonamide functionality (4a-d, 7a-c and 10) as well as hydroxamic acid (15a-b), carboxylic acid (16a-b), carboxamide (17a-b) and boronic acid (22a-b and 26) functionalities, which act as human carbonic anhydrase (hCA, EC 4.2.1.1) inhibitors. The newly synthesized benzimidazole derivatives were evaluated against 4 physiologically
我们描述了一系列带有磺酰胺官能团(4a-d,7a-c和10)以及异羟肟酸(15a-b),羧酸(16a-b),羧酰胺(17a-b)的2-芳基苯并咪唑衍生物的合成)和硼酸(22a-b和26)的功能,它们可作为人的碳酸酐酶(hCA,EC 4.2.1.1)抑制剂。对新合成的苯并咪唑衍生物针对4种生理相关的CA同工型(hCA I,II,IX和XII)进行了评估,尤其是含磺酰胺的苯并咪唑对KI的范围在KI值范围内的肿瘤相关CA IX和XII表现出令人感兴趣的抑制活性。分别为5.2-29.3 nM和9.9-41.7 nM。值得注意的是,化合物4c是最有效和选择性最高的CA IX(KI = 6.6 nM)和XII(KI = 9)。9 nM)抑制剂,相对于胞质CA I和II同工型具有显着的选择性比,范围在3.4-25.20之间。另外,具有KIX的微摩尔效价较低,具有异羟肟酸(15a-b)或羧酸(16a-b)官能度的化合物对CA